Payment overview · 2025
General Payments
$375.06
18 reported records · 8 companies
Healthcare provider profile · identity verified
Larry C Norris, P.A.
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · OPP, AL · NPI 1356343271
Verified facts
What the public records show
CMS Open Payments records show Larry C Norris, P.A. received $375.06 in general payments during 2025 across 18 reported records.
Lilly USA, LLC accounted for 45.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $170.86 | 45.6% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $69.75 | 18.6% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $50.85 | 13.6% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.92 | 5.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.85 | 5.0% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.36 | 4.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.69 | 3.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.78 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $356.21 | 17 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $157.22 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $69.75 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $50.85 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $32.49 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.92 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.92 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.79 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.69 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 67 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 290 | 51 |
| Montelukast Sodium | Montelukast Sodium | 224 | 53 |
| Losartan Potassium | Losartan Potassium | 219 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 219 | 65 |
| Simvastatin | Simvastatin | 173 | 41 |
| Levothyroxine Sodium | Levothyroxine Sodium | 172 | 38 |
| Atorvastatin Calcium | Atorvastatin Calcium | 148 | 45 |
| Tramadol Hcl | Tramadol Hcl | 146 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 144 | 38 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 135 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 119 | 28 |
| Potassium Chloride | Potassium Chloride | 118 | 37 |
| Omeprazole | Omeprazole | 106 | 32 |
| Trazodone Hcl | Trazodone Hcl | 106 | 27 |
| Furosemide | Furosemide | 105 | 30 |
| Amlodipine Besylate | Amlodipine Besylate | 103 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 95 | 27 |
| Sertraline Hcl | Sertraline Hcl | 89 | 24 |
| Lisinopril | Lisinopril | 86 | 31 |
| Metformin Hcl | Metformin Hcl | 80 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 18 |
| Farxiga | Dapagliflozin Propanediol | 68 | 14 |
| Ozempic | Semaglutide | 67 | suppressed |
| Azithromycin | Azithromycin | 63 | 53 |
| Buspirone Hcl | Buspirone Hcl | 63 | 12 |
| Celecoxib | Celecoxib | 63 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 16 |
| Meloxicam | Meloxicam | 59 | 13 |
| Allopurinol | Allopurinol | 51 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 51 | 13 |
| Naproxen | Naproxen | 50 | 14 |
| Alprazolam | Alprazolam | 49 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 48 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 11 |
| Meclizine Hcl | Meclizine Hcl | 46 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 45 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 44 | 14 |
| Glipizide | Glipizide | 44 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 39 | suppressed |
| Trulicity | Dulaglutide | 37 | suppressed |
| Clonazepam | Clonazepam | 33 | suppressed |
| Famotidine | Famotidine | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | suppressed |
| Eliquis | Apixaban | 31 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 31 | suppressed |
| Pregabalin | Pregabalin | 31 | suppressed |
| Carvedilol | Carvedilol | 30 | suppressed |
| Lorazepam | Lorazepam | 30 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 24 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 16 |
| Cefuroxime | Cefuroxime Axetil | 15 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 12 |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $375.06 · 18 records | Lilly USA, LLC | CAPLYTA, Cologuard Collection Kit, JARDIANCE, MOUNJARO, Ozempic, REXULTI, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error